Drug intelligence / Profile preview

A-620223

Development stage: Unknown
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral (as A-620223 Succinate)

Overview

A-620223 is a small molecule drug that acts as a potent inhibitor of poly(ADP-ribose) polymerase (PARP). It was initially developed by Abbott Laboratories and has shown efficacy in enhancing the effects of radiation and cytotoxic agents in rodent tumor models. The drug is primarily aimed at treating neoplasms.

Other names: 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-7-carboxamide1H-Benzimidazole-7-carboxamide, 2-(1-propyl-4-piperidinyl)-272769-49-0

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on A-620223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-620223.

Explore the full profile